Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03030235 · ClinicalTrials.gov registry record · Phase 4
Dapagliflozin in PRESERVED Ejection Fraction Heart Failure
A Phase 4 study of Chronic Heart Failure With Preserved Systolic Function, sponsored by Saint Luke's Health System.
- Completed
- Registry status
- Phase 4
- Development phase
- 324
- Enrollment target
- 20
- Study locations
NCT03030235 is a Phase 4 study of Chronic Heart Failure With Preserved Systolic Function that has completed, run by Saint Luke's Health System. The registered enrollment target is 324 participants. The trial reports 20 study locations across 13 states.
The verdict
NCT03030235, a Phase 4 study of Chronic Heart Failure With Preserved Systolic Function, has completed, sponsored by Saint Luke's Health System.
- COMPLETED
- Registry status
- Phase 4
- Development phase
- 324 participants
- Enrollment target
- 20
- Study locations
Study Summary
The primary purpose of this study is to evaluate the impact of dapagliflozin, as compared with placebo, on heart failure, disease specific biomarkers, symptoms, health status and quality of life in patients with chronic heart failure with preserved systolic function.
Conditions Studied
Interventions
- DRUG Dapagliflozin 10Mg Oral Tablet
- DRUG Dapagliflozin matching placebo
Study Locations (20)
Illinois
- NorthShore University HealthSystem Research Insititute - Evanston
- Northwestern University - Evanston
- Chicago Medical Research - Hazel Crest
- OSF HealthCare Cardiovascular Institute - Peoria
Florida
- First Coast Cardiovascular Institute - Jacksonville
- Charlotte Heart Group Research Center - Port Charlotte
Missouri
- Saint Luke's Mid America Heart Institute - Kansas City
- Washington University - St Louis
New York
- Columbia University - New York
- St. Francis Hospital - New York
North Carolina
- Eastern Nephrology Associates - New Bern
- Wake Forest University - Winston-Salem
Alabama
- Heart Group of the Eastern Shore - Fairhope
California
- University of Southern California - Los Angeles
Georgia
- Emory University - Atlanta
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 324 participants |
| Start Date | 2017-03-01 |
| Est. Completion | 2021-08-13 |
| Phase | Phase 4 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03030235
The ClinicalTrials.gov registry entry for NCT03030235 describes a study currently listed as completed, categorized as Phase 4. The registered enrollment target is 324 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Saint Luke's Health System, which has 26 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Chronic Heart Failure With Preserved Systolic Function appearing as the primary indexed condition, and to 2 interventions - of which Dapagliflozin 10Mg Oral Tablet is the first listed.
NCT03030235 reports 20 study locations spanning 13 distinct geographic areas - top geographies include Illinois, Florida, Missouri.
Frequently Asked Questions
What is clinical trial NCT03030235 about?
NCT03030235 is a clinical study titled "Dapagliflozin in PRESERVED Ejection Fraction Heart Failure". The primary purpose of this study is to evaluate the impact of dapagliflozin, as compared with placebo, on heart failure, disease specific biomarkers, symptoms, health status and quality of life in patients with chronic heart failure with preserved systolic function.
What is the current status of trial NCT03030235?
This trial is currently completed. It is a Phase 4 study. The enrollment target is 324 participants. The study started on 2017-03-01. Estimated completion is 2021-08-13.
What conditions does trial NCT03030235 study?
This clinical trial studies the following conditions: Chronic Heart Failure With Preserved Systolic Function.
What interventions are being tested in trial NCT03030235?
The interventions under investigation include: Dapagliflozin 10Mg Oral Tablet (DRUG), Dapagliflozin matching placebo (DRUG).
Who is sponsoring clinical trial NCT03030235?
This trial is sponsored by Saint Luke's Health System, which has 26 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT03030235 being conducted?
This trial has 20 study locations across Alabama, California, Florida, Georgia, Illinois. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.